[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100448952":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":26,"locations":35,"responsibleParty":63,"collaborators":18,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":18,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"National Taiwan University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hydroxychloroquine","EXPERIMENTAL","Hydroxychloroquine 200mg twice daily for 6 months.",[13],"Drug: Hydroxychloroquine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Observation and active surveillance.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.",[9],[25],"Plaquenil",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},"Shyang-Rong Shih","CONTACT","+886-2-23123456","srshih@ntu.edu.tw",{"name":33,"role":29,"phone":30,"phoneExt":18,"email":34},"Hung-Yuan Li","larsli@ntuh.gov.tw",[36,53],{"facility":37,"status":38,"city":39,"state":18,"zip":18,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"National Taiwan University Hospital, Hsin-Chu branch","RECRUITING","Hsinchu","Taiwan","TW",{"type":43,"coordinates":44},"Point",[45,46],120.96861,24.80361,{"lat":46,"lon":45},[49],{"name":50,"role":29,"phone":51,"phoneExt":18,"email":52},"Chia-Hung Lin, M.D.","+886-3-6677600","chiahunglin@ntuh.gov.tw",{"facility":5,"status":38,"city":54,"state":18,"zip":18,"country":40,"countryCode":41,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Taipei",{"type":43,"coordinates":56},[57,58],121.52639,25.05306,{"lat":58,"lon":57},[61,62],{"name":28,"role":29,"phone":30,"phoneExt":18,"email":31},{"name":33,"role":29,"phone":30,"phoneExt":18,"email":34},{"type":64,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100448952","phase-4-hydroxychloroquine-in-mild-graves-orbitopathy-100448952",false,"NCT05126147","Hydroxychloroquine in Mild Graves' Orbitopathy","A Randomized Controlled Trial on the Effect of Hydroxychloroquine in Mild Graves' Orbitopathy","Inclusion Criteria:\n\n* Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist.\n* No previous treatment of GO except for eyedrops\n* Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months.\n\nExclusion Criteria:\n\n* Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist.\n* Pregnancy\n* Drug or alcohol abuse\n* Unable to comply with the study protocol\n* Unable to obtain informed consent\n* Use of hydroxychloroquine or systemic steroid within 3 months prior to enrollment\n* History of side effects of hydroxychloroquine\n* History of retinopathy\n* Renal dysfunction (estimated glomerular filtration rate (eGFR) \\\u003C 60ml\u002Fmin)\n* Hepatic dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2 x upper limit)\n* Anemia (hemoglobin (Hb) \\\u003C 10g\u002Fdl)\n* Neutropenia (absolute neutrophil count \\\u003C 100\u002FuL)\n* Thrombocytopenia (platelet (PLT) \\\u003C 150000\u002FuL)\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* Porphyria cutaneous tarda\n* Allergy to 4-aminoquinoline","ALL","18 Years","75 Years",{"count":76,"type":77},108,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).",[83],"Graves Ophthalmopathy",[85,86,9,87,88],"Graves' ophthalmopathy","Graves' disease","Orbital volumetry","GO-QoL questionnaire","2025-02-23",{"date":91,"type":92},"2025-02-25","ACTUAL",{"date":94,"type":92},"2022-03-21",{"date":96,"type":77},"2026-12-31",{"name":5,"class":6},2]